Occlutech Wins Swedish Court Ruling Against AGA-St Jude Medical

JENA, Germany, March 4, 2011 - Occlutech GmbH, a leading European developer of minimally invasive
implants for the treatment of structural heart disease, today announced that
it has received a favourable court ruling from Stockholm, Sweden in the
on-going patent litigation with AGA Medical -St Jude Medical.

In the ruling by Stockholms tingsratt , the district court of Stockholm,
the court does not see any basis for AGA-St Jude's claim that the Occlutech
ASD and PFO occluders violate any patent brought forward in the litigation.
The Stockholm court decision thus is similar to the first instance ruling in
the UK which was confirmed by the appeal court in the UK, the last one
received mid 2010. The UK ruling is final as the UK supreme court did not
allow an appeal requested by AGA. The favourable Stockholm ruling is also
similar to first instance as well as appeal court decisions in The Hague, in
the Netherlands, the last one obtained in the end of 2010.

The rulings in Sweden and The Netherlands are subject to appeal by AGA-St
Jude Medical.

Throughout the litigation, Occlutech's owners and investors have funded
work in maintaining and substantially strengthening Occlutech's own patent
position. Meanwhile, a full pipe line of new technologies and products have
been developed. In 2011 and 2012 Occlutech expects to launch additional
occluders for indications such as PDA and VSD in addition to second
generation ASD and PFO occluders. Also, an innovative LAA occluder, a new
generation of stent grafts and cardiac valve intervention technologies are
being developed.

Tor Peters, +49-3641-67-51-29, tor.peters at occlutech.com Katrin Biedermann, +49-3641-67-51-20, katrin.biedermann at occlutech.de